# Pituitary Hemorrhage in Hemolytic Uremic Syndrome

Toshiro Nagai, MD\*<sup>‡</sup>, Osamu Hasegawa, MD\*<sup>‡</sup>, Atsutoshi Tuji, MD<sup>†‡</sup>, Yasunori Kamiyama, MD\*<sup>‡</sup>, Masataka Honda, MD\*<sup>‡</sup>, and Hiroshi Ito, MD\*<sup>‡</sup>

A 5-year-old girl with hemolytic uremic syndrome is reported with pituitary hemorrhage in the acute phase. Seizures, hemiplegia, and transient blindness were observed. These symptoms cannot be attributed to the pituitary hemorrhage; however, pituitary hemorrhage should be added to the list of neurologic lesions that can occur in hemolytic uremic syndrome.

Nagai T, Hasegawa O, Tuji A, Kamiyama Y, Honda M, Ito H. Pituitary hemorrhage in hemolytic uremic syndrome. Pediatr Neurol 1992;8:75-6.

## Introduction

Neurologic complications of hemolytic uremic syndrome (HUS) include generalized or focal seizures, alterations of consciousness, hemiparesis, and coma [1,2]. Reported computed tomographic (CT) findings range from normal to diffuse cerebral edema, large-vessel infarctions, diffuse, multiple small-vessel infarctions, or hemorrhage [3-6]. The causes of HUS are considered to be multifactorial but, recently, verotoxin-producing *Escherichia coli* infection was proposed as one of the causal factors [7]. We report a girl with HUS probably associated with *E. coli* 0-157:H7 infection. She demonstrated severe neurologic complications with pituitary hemorrhage on CT in the acute phase of HUS.

#### **Case Report**

An epidemic of HUS occurred at a kindergarten in the eastern Tokyo Metropolitan area in October, 1990. During this period we examined a 5-year-old girl who was admitted to our hospital with anuria after

From the \*Division of Pediatrics; Tokyo Metropolitan Kiyose Children's Hospital; Tokyo, Japan; <sup>†</sup>Division of Pediatrics; Urawa City Hospital; Urawa, Japan; <sup>‡</sup>Division of Pediatrics; Keio University School of Medicine; Tokyo, Japan. prodromal gastroenterocolitis manifested by watery-loose and bloody stools.

On admission, she was alert with pale skin but without petechiae or ecchymosis. Blood pressure was 110/70 mm Hg. The platelet count was 71,000/mm<sup>3</sup> and fragmented erythrocytes were observed on peripheral smear. Hemoglobin was 10.7 gm/dl, hematocrit 30%, BUN 102 mg/dl, serum creatinine 4.5 mg/dl, serum sodium 139 mEq/L, potassium 4.7 mEq/L, chloride 103 mEq/L, and calcium 7.3 mg/dl. Blood gas analysis disclosed pH 7.32 and bicarbonate 15 mEq/L. IgM antibody assessed by the Widal method against somatic antigen for *E. coli* strain 0-157:H7 was increased on admission (× 320) and decreased 1 month later (× 80). Antiverotoxin antibody levels of both antiverotoxin<sub>1</sub> and antiverotoxin<sub>2</sub>. Stool culture confirmed the presence of *E. coli* 0-157:H7.

Three hours after admission, she developed generalized tonic seizures with poor response to antiepileptic drugs. Funduscopic examination revealed no hemorrhage and no cotton-wool spots on the retina.

The initial cranial CT on admission disclosed a high-density lesion in the pituitary gland with no evidence of large-vessel infarctions, no hemorrhage in the centrum semiovale, and no cerebral edema (Fig 1). There were no abnormalities of the geniculate bodies, calcarine cortex, or optic radiations.

The child's hospital course was characterized by prolonged oliguria lasting about 1 month, blindness for longer than 2 months, and spastic hemiplegia for 2 months. Continuous, ambulatory, peritoneal dialysis therapy was successfully performed without hypertension or electrolyte imbalance. During the period of blindness, pupillary responses to light were elicited but were slow and incomplete. Three months after admission, she had no neurologic deficits and her renal function was normal.

Serial CT scans obtained weekly in the acute phase revealed a persistent high-density lesion in the pituitary. Magnetic resonance imaging (MRI) performed 1 month after admission demonstrated high intensity in the  $T_1$  image and low intensity in the  $T_2$  image (Fig 2), suggesting hemosiderin deposit in the pituitary.

Two months after admission, endocrinologic studies were performed. Luteinizing hormone and thyrotropin-releasing hormone loading tests




Figure 1. On admission, unenhanced axial CT (5 mm thick section) demonstrates high-density lesion at the pituitary gland. This high-density lesion remained unchanged for more than 1 month.

Communications should be addressed to: Dr. Nagai; Division of Pediatrics; Tokyo Metropolitan Kiyose Children's Hospital; 1-3-1 Kiyose Umezono; Tokyo, Japan 204. Received July 30, 1991; accepted September 16, 1991.




Figure 2. Sagittal MRI obtained 1 month after admission discloses a hypointense lesion at the pituitary gland by  $T_2$  image.

disclosed a normal response to luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone. Arginine (0.5 gm/kg) and insulin (0.1 IU/kg) loading tests revealed an inadequate response of growth hormone (3.0  $\rightarrow$  9.3; 5.1  $\rightarrow$  6.8 ng/ml, respectively). The adrenocorticotropic hormone (ACTH) and cortisol response to insulin loading also documented an unsatisfactory response: ACTH (31  $\rightarrow$  42 pg/ml) and cortisol (7.96  $\rightarrow$  17.27 µg/100 ml).

### Discussion

The pathogenesis of neurologic complications of HUS has not been elucidated. Many metabolic disturbances encountered in this syndrome – hypertension, volume overload, hyponatremia, acid-base changes, hypocalcemia, intravascular coagulation, and microthrombi in the central nervous system (CNS) – may be considered to be causal factors. Intravascular coagulation and microthrombi in the kidney are the hallmark of this syndrome; however, these changes have not been consistently present in the CNS in autopsied cases [1,8].

Our patient had a renal disorder; however, because her metabolic disturbance was relatively mild (normal sodium and calcium concentration and normal blood pressure), her neurologic complications cannot be attributed to the metabolic disturbances. Radiologic examination revealed no infarction, but pituitary hemorrhage was observed. Cranial CT changes reported in this syndrome are various [3-6]; pituitary hemorrhage, however, has not been reported.

Clinically, she demonstrated inadequate response of ACTH and growth hormone to anterior pituitary gland stimulation tests. She now has no apparent sign of ACTH or growth hormone deficiency, but is being carefully monitored. Ocular involvement, especially cortical blindness, has been described occasionally in HUS [2,9,10] and retinal thrombi and opacity also have been reported [11]. The blindness usually is transient and no permanent blindness has been described in the literature. Our patient had no retinal lesions or detectable lesions of the optic tract or cortex on CT and MRI. Pituitary hemorrhage can compress the optic chiasm and cause a visual disturbance. We could not demonstrate such compression of the optic chiasm on CT or MRI; however, we speculate that her transient blindness may be related to pituitary hemorrhage.

Since the initial description by Karmali et al. [7], the causal relationship between HUS and antiverotoxinproducing *E. coli*, especially *E. coli* 0-157:H7, infection has been suspected [9,12-14]. We are uncertain whether there is any correlation between antiverotoxin-producing *E. coli* infection and pituitary hemorrhage. These two processes may have occurred in this patient coincidentally; however, because verotoxin causes vascular toxicity in the kidney and neurotoxicity in the CNS at the same time [15], we speculate that there may be some correlation between antiverotoxin-producing *E. coli* infection and pituitary hemorrhage pathologically.

We are indebted to Tae Takeda (National Children's Research Center) for performing the verotoxin study and would like to thank Dr. Mitsuru Osano, Keio University School of Medicine, for reviewing the manuscript.

#### References

[1] Rooney JC, Anderson MR, Hopkins IJ. Clinical and pathological aspects of central nervous system involvement in the hemolyticuremic syndrome. Aust Paediatr J 1971;7:28-33.

[2] Sheth KL, Swick HM, Haworth N. Neurologic involvement in hemolytic-uremic syndrome. Ann Neurol 1986;19:90-3.

[3] Mendelsohn DB, Hertzanu Y, Chaitowitz B, Cartwright JD. Cranial CT in the hemolytic uremic syndrome. J Neurol Neurosurg Psychiatry 1984;47:876-8.

[4] **DiMario** FJ, Bronte-Stewart H, Sherbotie J, Turner ME. Lacunar infarction of the basal ganglia as a complication of hemolyticuremic syndrome. Clin Pediatr 1987;26:586-90.

[5] Trevathan E, Dooling EC. Large thrombotic strokes in hemolytic-uremic syndrome. J Pediatr 1987;111:863-6.

[6] Hahn JS, Havens PL, Higgins JJ, et al. Neurological complications of hemolytic-uremic syndrome. J Child Neurol 1989;4:108-13.

[7] Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of hemolytic-uremic syndrome associate with facal cytotoxin and cyto-toxin-producing *Escherichia coli* in stools. Lancet 1983;19:619-20.

[8] Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo GE, Sojo ET. The hemolytic-uremic syndrome. Nephron 1973;11:174-92.

[9] Martin DL, Kristine MPH, MacDonald L, White K, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 1990;323:1161-7.

[10] Kahn SI, Tolkan SR, Kothari O, Garella S. Spontaneous recovery of the hemolytic uremic syndrome with prolonged renal and neurological manifestations. Nephron 1982;32:188-91.

[11] Siegler RL, Brewer ED, Swartz M. Ocular involvement in hemolytic-uremic syndrome. J Pediatr 1988;112:594-7.

[12] Gransden WR, Damm MA, Anderson JD, Carter JE, Lior H. Further evidence associating hemolytic uremic syndrome with infection by verotoxin-producing *Escherichia coli* 0157:H7. J Infect Dis 1986; 154:522-4.

[13] Carter AO, Borczyk AA, Carlson JAK, Krishnan C, Korn DA, Lior H. A severe outbreak of *Escherichia coli* 0157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987;317:1496-500.

[14] Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H. Hemolytic uremic syndrome in the British Isles 1985-8: Association with verotoxin producing *Escherichia coli*, Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990;65:716-21.

[15] Keusch GT, Grady GF, Mata LJ, McClever J. The pathogenesis of *Shigella* toxin. J Clin Invest 1972;51:1212-8.